3/13/2013

Biogen Idec has filed a biologics license application with the FDA for approval to use recombinant factor VIII Fc fusion protein as a treatment for hemophilia A. The drug belongs to a new class of long-lasting clotting factor treatments. The application was based on positive results of the late-stage A-LONG trial.

Full Story:
RTT News

Related Summaries